Cardio Kidney Diabetes... The Triple Threat

A new CKD Paradigm

Global Consensus Conference

Renaissance Chicago Hotel

October 17- 19, 2007

1 West Wacker Drive/Chicago, IL 60601

Wednesday, October 17, 2007 Welcome Reception and Dinner

5:30 pm - 8:00 pm

Conference Check-in • Grand Ballroom Foyer

6:30 pm - 7:30 pm

Welcome Reception • Grand Ballroom Foyer

7:30 pm - 9:30 pm

Dinner/Opening Remarks • Grand Ballroom V

Conference Co-Chairs: George Bakris MD, Mark E. Molitch MD & Richard W. Nesto MD

Thursday, October 18, 2007

Plenary Session; followed by Work Group Breakout Sessions

6:30 am - 7:30 am Conference Check-in & Continental Breakfast • Grand Ballroom Foyer

7:30 am – 12:00 noon • Grand Ballroom I-III
Plenary Session: Influence of Early Kidney Disease

on Cardiovascular Injury and Events

7:30 am – 7:45 am Welcome and Opening Remarks

George Bakris MD and Joseph Vassalotti MD, FASN

7:45 am – 8:15 am I: Epidemiology of Kidney Disease on Cardiovascular Risk

Moderator: George Bakris MD

7:45 am - 8:05 am

Role of Proteinuria to Define Cardiovascular Risk

Katherine R. Tuttle MD, FASN, FACP

8:05 am - 8:15 am Questions/Discussion

Thursday, October 18, 2007 (continued)
Plenary Session: 7:30 am – 12:00 noon • Grand Ballroom I-III

8:15 am – 9:00 am II: Interaction between Diabetes and Cardiovascular Disease

Moderator: George Bakris MD

8:15 am - 8:30 am

Impact of Insulin Sensitizers on Diabetes and Cardiovascular Risk

Willa A. Hsueh MD

8:30 am - 8:45 am

Exploring the link between Diabetes and Cardiovascular Disease

Richard W. Nesto MD

8:45 am - 9:00 am

Questions/Discussion

9:00 am - 10:00 am III: Effects of Early Kidney Disease on Atherosclerosis Progression

Moderator: George Bakris MD

9:00 am - 9:20 am

Influence of Early Kidney Disease on Atherosclerotic Mechanisms

Christoph Wanner MD

9:20 am - 9:40 am

Changes in Vascular Function and Predisposition to Accelerated

Atherosclerosis

Michael Davidson, MD

9:40 am - 10:00 am

Questions/Discussion

10:00 am- 10:15 am Morning Break • Grand Ballroom Foyer

10:15 am – 11:00 am IV: Early Kidney Disease and Heart Failure

Moderator: Richard W. Nesto MD

10:15 am - 10:45 am

Interactions of Early Kidney Disease on the Failing Heart

John C. Burnett Jr., MD

10:45 am – 11:00 am Questions/DiscussionThursday, October 18, 2007 (continued)

Plenary Session: 7:30 am – 12:00 noon • Grand Ballroom I-III

11:00 am – 12:00 noon V: Influence of Glucose Abnormalities on Vascular Injury

in Kidney Disease

Moderator: Richard W. Nesto MD

11:00 am - 11:20 am

Influence of Metabolic Syndrome on Cardiovascular Risk

in the Presence of Early Kidney Disease

Steven M. Haffner MD

11:20 am - 11:40 am

New Onset Diabetes and Cardiovascular Disease in Early Kidney Disease

George Bakris MD

11:40 am – 12:00 noon Questions/Discussion

12:00 noon – 1:00 pm Lunch for Conference Participants • Grand Ballroom V

1:00 pm – 5:30 pm Work Group Breakout Sessions

Conference participants will each join one of the following 4 Work Groups for the remainder of the day. Each Work Group will develop a presentation about their discussion/recommendations for the next day.

Work Group I: Influence of Blood Pressure Targets on

• Grand Ballroom IV Vascular Injury in Chronic Kidney Disease

Work Group Leader: Eberhard Ritz MD

Work Group II: Impact of Dyslipidemia Management on

LaSalle Atherosclerosis Progression in Chronic Kidney Disease

Work Group Leaders: Christoph Wanner MD

and George Kaysen MD, PhD

Work Group III: Impact of Glycemic Control on Vascular Injury in Chronic Kidney Disease

Hudson A/B Work Group Leader: James R. Sowers MD

Work Group IV: Clinical Implications for Interactions of Chronic Kidney Disease

Michigan on Vascular Injury

Work Group Leader: John C. Burnett Jr., MD

3:30 pm - 3:45 pm: Refreshment Break •

Grand Ballroom Foyer

6:30 pm – until Dinner • Grand Ballroom V-VI

After dinner: Work Group Leaders will continue preparing their Powerpoint presentations for the next day (along with Work Group participants, if needed). Work Group rooms will be available until late Thursday night, for those who wish to continue.

Friday, October 19, 2007

Plenary Session for Work Group Reports (Open to the public)

7:30 am – 8:30 am Conference Check-in & Continental Breakfast • Grand Ballroom Foyer

8:30 am – 12:00 noon • Grand Ballroom I - III

Plenary Session: Work Group Reports

Each Work Group will have 20 minutes to present their discussion points and recommendations, followed by 20 minutes for Questions/Discussion with the Plenary Group.

Moderators: George Bakris MD, Mark E. Molitch MD, Richard W. Nesto MD

8:30 am – 8:50 am Work Group I Presentation:

Influence of Blood Pressure Targets on Vascular Injury

in Chronic Kidney Disease (Work Group Leader: Eberhard Ritz MD)

8:50 am – 9:10 am Questions/Discussion

9:10 am – 9:30 am Work Group II Presentation:

Impact of Dyslipidemia Management on Atherosclerosis Progression

in Chronic Kidney Disease (Work Group Leaders: Christoph Wanner MD and

George Kaysen MD, PhD)

9:30 am - 9:50 am: Questions/Discussion

9:50 am - 10:00 am Morning Break • Grand Ballroom Foyer

10:00 am – 10:20 am Work Group III Presentation:

Impact of Glycemic Control on Vascular Injury in Chronic Kidney

Disease (Work Group Leader: James R. Sowers MD)

10:20 am – 10:40 am: Questions/Discussion

10:40 am - 11:00 am Work Group IV Presentation:

Clinical Implications for Interactions of Chronic Kidney Disease on Vascular Injury (Work Group Leader: John C. Burnett Jr., MD)

11:00 am - 11:20 am: Questions/Discussion

11:20 am – 11:30 am Wrap Up and Next Steps George Bakris MD

11:30 am: Conference Adjourns

11:30 am: Lunch Available for all Participants • Grand Ballroom IV

11:45 am – 1:00 pm Lunch and Wrap-Up Meeting (next steps, educational

activities/initiatives) for Conference Co-Chairs, Work Group Leaders,

and Speakers only • LaSalle

The National Kidney Foundation would like to thank the following organizations, whose generous support made this important conference possible:

Abbott

sanofi-aventis

Amgen

Boehring Ingelheim

Pfizer

Quest Diagnostics

Merck

Takeda Pharmaceuticals